Ranbaxy Cleared To Launch Diovan Generic In U.S. With Exclusivity
This article was originally published in PharmAsia News
Ranbaxy Laboratories is free to launch its generic version of the Novartis drug Diovan (valsartan) for treating high blood pressure in the U.S. after gaining U.S. FDA approval.
You may also be interested in...
A US lawsuit accusing Sun Pharma’s Ranbaxy of violating racketeering and antitrust laws, thereby maintaining artificially inflated prices for three blockbuster drugs, is now set to go to trial in January next year, after a US district court in Massachusetts denied all motions for summary judgment.
The US Food and Drug Administration has launched a new webpage dedicated to medical devices that incorporate augmented reality and virtual reality technologies. The agency has approved some 39 AR/VR devices.
Medtech Insight's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – in vitro diagnostics and medical devices – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in November 2022. Data provided by Citeline's Biomedtracker.